Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.

Targeted therapeutic and diagnostic nanocarriers functionalized with antibodies, peptides or other targeting ligands that recognize over-expressed receptors or antigens on tumor cells have potential in the diagnosis and therapy of cancer. Somatostatin receptors (SSTRs) are over-expressed in a variety of cancers, particularly neuroendocrine tumors (NETs) and can be targeted with somatostatin peptide analogs such as octreotate (TATE). In the present study we investigate liposomes that target SSTR in a NET xenograft mouse model (NCI-H727) by use of TATE. TATE was covalently attached to the distal end of DSPE-PEG(2000) on PEGylated liposomes with an encapsulated positron emitter (64)Cu that can be utilized for positron emission tomography (PET) imaging. The biodistribution and pharmacokinetics of the (64)Cu-loaded PEGylated liposomes with and without TATE was investigated and their ability to image NETs was evaluated using PET. Additionally, the liposome accumulation and imaging capability was compared with free radiolabelled TATE peptide administered as (64)Cu-DOTA-TATE. The presence of TATE on the liposomes resulted in a significantly faster initial blood clearance in comparison to control-liposomes without TATE. PEGylated liposomes with or without TATE accumulated at significantly higher quantities in NETs (5.1±0.3 and 5.8±0.2 %ID/g, respectively) than the free peptide (64)Cu-DOTA-TATE (1.4±0.3 %ID/g) 24 h post-injection. Importantly, (64)Cu-loaded PEGylated liposomes with TATE showed significantly higher tumor-to-muscle (T/M) ratio (12.7±1.0) than the control-liposomes without TATE (8.9±0.9) and the (64)Cu-DOTA-TATE free peptide (7.2±0.3). The higher T/M ratio of the PEGylated liposomes with TATE suggests some advantage of active targeting of NETs, although no absolute benefit in tumor accumulation over the non-targeted liposomes was observed. Collectively, these data showed that (64)Cu-loaded PEGylated liposomes with TATE conjugated to the surface could be promising new imaging agents for visualizing tumor tissue and especially NETs using PET.

[1]  E P Krenning,et al.  Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. , 1998, Cancer research.

[2]  R. Schiffelers,et al.  Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Russell J Mumper,et al.  Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Andreas Kjær,et al.  64Cu loaded liposomes as positron emission tomography imaging agents. , 2011, Biomaterials.

[5]  Samuel Zalipsky,et al.  In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  I. Rubinstein,et al.  VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Thomas L Andresen,et al.  Liposomal cancer therapy: exploiting tumor characteristics , 2010, Expert opinion on drug delivery.

[8]  Ulrik B Nielsen,et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  U. Kumar,et al.  Biology of somatostatin in breast cancer , 2008, Molecular and Cellular Endocrinology.

[10]  Nicholas A Peppas,et al.  Targeted Nanodelivery of Drugs and Diagnostics. , 2010, Nano today.

[11]  G. Bendas,et al.  VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. , 2008, Biochimica et biophysica acta.

[12]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[13]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[14]  R Laforest,et al.  Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. , 2000, Cancer biotherapy & radiopharmaceuticals.

[15]  C. Beglinger,et al.  Preclinical Comparison in AR4-2J Tumor-Bearing Mice of Four Radiolabeled 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Somatostatin Analogs for Tumor Diagnosis and Internal Radiotherapy. , 2000, Endocrinology.

[16]  Wolfgang A. Weber,et al.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[17]  I. Virgolini,et al.  Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? , 1997, European journal of clinical investigation.

[18]  K. Syrigos,et al.  Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model , 2000, British Journal of Cancer.

[19]  A. Kjaer,et al.  Quantitative Gene Expression of Somatostatin Receptors and Noradrenaline Transporter Underlying Scintigraphic Results in Patients with Neuroendocrine Tumors , 2008, Neuroendocrinology.

[20]  T. Andresen,et al.  Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.

[21]  Yechezkel Barenholz,et al.  Liposome application: problems and prospects , 2001 .

[22]  K. Syrigos,et al.  Biodistribution and pharmacokinetics of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies , 2000, British Journal of Cancer.

[23]  A. Gabizon,et al.  Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. , 1990, Cancer research.

[24]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[25]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[26]  Pauline Chu,et al.  A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. , 2004, International journal of radiation oncology, biology, physics.

[27]  J. Klijn,et al.  Somatostatin receptors in human endocrine tumors. , 1987, Cancer research.

[28]  V. Torchilin,et al.  Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes. , 2006, Molecular pharmaceutics.

[29]  W. Phillips,et al.  Delivery of gamma-imaging agents by liposomes. , 1999, Advanced drug delivery reviews.

[30]  Qiang Zhang,et al.  A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. , 2010, Molecular pharmaceutics.

[31]  D. Ribatti,et al.  Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.

[32]  P. Neuhaus,et al.  Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues , 2004, Langenbecks Archiv für Chirurgie.